Published in final edited form as:

Drug Alcohol Depend. 2019 January 01; 194: 244–251. doi:10.1016/j.drugalcdep.2018.10.016.

Lack of effect of transcranial direct current stimulation (tDCS) on short-term smoking cessation: Results of a randomized, sham-controlled clinical trial

Mary Falcone^a, Leah Bernardo^a, E. Paul Wileyto^a, Cheyenne Allenby^a, Anne Marie Burke^a, Roy Hamilton^b, Mario Cristancho^a, Rebecca L. Ashare^a, James Loughhead^a, and Caryn Lerman^a

^aDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

^bLaboratory for Cognition and Neural Stimulation, University of Pennsylvania, Philadelphia, PA, USA

Abstract

Background: Transcranial direct current stimulation (tDCS) has been shown to improve measures of executive cognitive function and reduce cigarette consumption. Studies conducted to date have been small, and the results are mixed.

Methods: This randomized, double-blind, parallel arm clinical trial tested the effects of active anodal tDCS targeted to the left dorsolateral prefrontal cortex (versus sham) on 7-day smoking cessation in 106 treatment-seeking smokers. Participants received three sessions of sham ($n = 35$), 1mA ($n = 35$), or 2mA ($n = 36$) tDCS in the context of a validated smoking lapse paradigm then received brief smoking cessation counseling and completed a monitored quit attempt. The primary outcome was total number of days of abstinence confirmed via exhaled carbon monoxide.

Results: During the quit period, there were no effects of dose group on days of abstinence (sham, $M (SD): 2.5 \text{ days } (\pm 2.5)$; 1mA: $2.5 \text{ days } (\pm 2.5)$; 2mA: $2.4 \text{ days } (\pm 2.3)$; $\beta = -0.08$; $p = 0.76$) or on change in daily smoking rate (sham, $M (SD): -12.6 \text{ CPD } (\pm 4.8)$; 1mA: $-11.8 \text{ CPD } (\pm 4.4)$; 2mA: $-11.7 \text{ CPD } (\pm 5.3)$; $\beta = 0.42$, $p = 0.49$), nor were there effects of dose group on latency to smoke or number of cigarettes smoked during the smoking lapse paradigm. Side effects of tDCS were generally mild (<5 out of 10), and participants were not able to distinguish between active and sham treatment.

Correspondence Mary Falcone, Center for Interdisciplinary Research on Nicotine Addiction, 3535 Market Street, Suite 4100, University of Pennsylvania, Philadelphia, PA, 19104, +1 (215) 746-3782, mfalc@pennmedicine.upenn.edu.

Contributors

Dr. Lerman conceived of and led the project. Drs. Falcone, Ashare, and Loughhead contributed to the study design and selection of measures. Dr. Cristancho served as study physician. Dr. Hamilton developed the tDCS procedures and supervised the training of the tDCS technicians. Ms. Bernardo and Ms. Burke contributed to study design and served as study coordinators. Drs. Falcone and Wileyto and Ms. Allenby developed and conducted the analytical approach. All authors contributed to the development of the manuscript and approved the final version.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest
None.

Conclusions: These results do not support the efficacy of tDCS targeted to the left dorsolateral prefrontal cortex (DLPFC) for smoking cessation.

Keywords

Smoking Cessation; Cognitive Control; Brain Stimulation; tDCS

1. Introduction

Tobacco use is one of the leading causes of preventable death and illness worldwide (Global Burden of Disease Research Foundation Collaborators, 2016; WHO, 2017), yet the majority of smokers who want to quit are unable to maintain abstinence even for a few days (Babb et al., 2017; Hughes et al., 2004). Many factors contribute to relapse, and existing treatments offer support for the most prominent factors such as withdrawal symptoms and cravings (Aubin et al., 2014; Piper et al., 2011; Shiffman et al., 2006). However, subtle deficits in executive cognitive function emerging during the first 24 hours of abstinence may also contribute to relapse (Ashare et al., 2014; Loughhead et al., 2015; McClernon et al., 2015). Such effects may reduce cognitive control over reward-driven or impulsive behaviors (such as smoking a cigarette) (Botvinick and Braver, 2014; Braver et al., 2014).

Functional magnetic resonance imaging (fMRI) studies have revealed a network of brain regions contributing to cognitive control; collectively, these regions are known as the executive control network (ECN) (Fox et al., 2005; Vincent et al., 2008). One region within this network is the dorsolateral prefrontal cortex (DLPFC), which has been implicated in working memory and attentional control (D'Esposito and Postle, 2014; Fassbender et al., 2004). During abstinence, smokers show alterations in connectivity between large scale networks including the ECN (Cole et al., 2010; Fedota et al., 2018; Lerman et al., 2014) as well as reductions in DLPFC activation that predict relapse above and beyond clinical and behavioral measures (Loughhead et al., 2015; Wilcox et al., 2017). Therefore, treatments targeting DLPFC activation offer a novel therapeutic approach to smoking cessation (McClernon et al., 2015).

Recently, there has been a surge of interest in non-invasive methods to stimulate brain activity for the treatment of addiction (Coles et al., 2018). One such method is transcranial direct current stimulation (tDCS), a technique in which light electrical currents (1–2mA) are applied to the scalp over targeted regions of the brain. Initial studies suggest that active anodal tDCS targeted to the right or left DLPFC can reduce cravings to smoke (Fregni et al., 2008; Yang et al., 2017) as well as latency to smoke in the laboratory (Falcone et al., 2016) and daily smoking rates (Boggio et al., 2009; Fecteau et al., 2014; Vitor de Souza Brangioni et al., 2018). However, other studies found no changes in craving (Kroczeck et al., 2016; Pripfl and Lamm, 2015; Smith et al., 2015; Xu et al., 2013) or found that reductions in craving did not transfer to changes in smoking behavior (Mondino et al., 2018). Variation in reported outcomes may be related to small sample sizes ($n \approx 10\text{--}40$ subjects per trial), differences in baseline smoking rates (studies with non-significant outcomes may include more light or non-daily smokers than those which reported significant effects), or differences

in treatment protocols (i.e., intensity, duration, and number of sessions). Further research is necessary in order to identify optimal treatment conditions.

This parallel arm randomized double-blind clinical trial evaluated the effects of three anodal tDCS treatments (sham/placebo, 1mA, or 2mA dose) targeted to the left DLPFC on short-term smoking cessation. Our primary outcome was the number of days of abstinence during a 7-day monitored abstinence period, a brief cessation model shown to be highly predictive of 6-month smoking cessation rates (Ashare et al., 2013). Secondary outcomes were latency to smoke and total number of cigarettes smoked during a laboratory smoking lapse paradigm completed during the stimulation sessions (Falcone et al., 2016). We predicted a positive dose response effect of tDCS (2mA > 1mA > sham) on the total number of days of abstinence during the quit period and on the ability to resist smoking during the laboratory sessions.

2. Materials and methods

2.1 Participants

All procedures were approved by the University of Pennsylvania Institutional Review Board and carried out in accordance with the Declaration of Helsinki. Healthy adults between the ages of 18 and 60 who reported smoking at least 10 cigarettes per day (CPD) for the past year and who expressed an intent to quit or reduce smoking in the next 3 months were recruited through mass media between November 2015 and March 2018 in the greater Philadelphia area. We recruited participants who reported that they intended to quit smoking in the next 3 months in order to identify likely treatment-seeking smokers, who have been shown to respond differently to smoking cessation treatments than non-treatment seekers (Perkins and Lerman, 2014). Self-reported intent to quit or reduce smoking is a strong predictor of subsequent quit attempts (Hyland et al., 2006; Vangeli et al., 2011; Perkins and Lerman, 2014). All participants provided written informed consent and completed an in-person eligibility screen including a breath alcohol test and a carbon monoxide (CO) breath assessment to confirm tobacco exposure; participants with a positive breath alcohol test or an exhaled CO <10ppm were excluded (SRNT Subcommittee on Biochemical Verification, 2002). Female participants completed a urine pregnancy test. Participants who self-reported a history of DSM-IV Axis I psychiatric or substance use disorders (except nicotine dependence) or the use of psychotropic medications were excluded. Additional exclusion criteria included current or recent use (past two weeks at eligibility assessment) of smoking cessation medications; pregnancy, breastfeeding, or planning a pregnancy; history of stroke, seizure disorder, brain injury or tumor; skull fracture or opening; pacemakers or metallic objects in the face or head (other than dental apparatus); low or borderline intellectual functioning (estimated IQ <85 on Shipley Institute of Living Scale); and any impairment that would prevent task performance. Figure 1 shows the CONSORT flow diagram for the study.

2.2 Procedures

This study used a between-subject, randomized and double-blind design. Participants were assigned to one of three tDCS dosage groups (1mA, 2mA, or sham) in a 1:1:1 allocation

ratio using simple randomization with replacement. Randomization was handled by the data management team: following confirmation of eligibility, a research assistant entered participant information into a study database which automatically assigned them to the next available randomization slot stratified by nicotine dependence [Fagerström Test for Nicotine Dependence (FTND) >5 vs. FTND ≤5]. A collection of five-digit codes was associated with each dose group and were given to the tDCS technician for use during the sessions (see section 2.4 for details). Procedures for each group were identical: all participants completed three stimulation sessions over the course of one week (days 1, 3, 5) followed by a 7-day monitored abstinence period (framed as a ‘practice quit attempt’) consisting of 4 in-person visits (days 6, 8, 10, 12) to confirm smoking status.

Participants were abstinent for 18 hours prior to each stimulation session. Abstinence was biochemically confirmed by exhaled CO reading at the start of the session. At Session 1, exhaled CO was required to be less than 10ppm or at least a 50% reduction from the reading at their eligibility screen. At subsequent sessions, participants were instructed to remain abstinent for 18 hours and exhaled CO was assessed, but due to the potential for unanticipated effects of tDCS on smoking behavior participants were not withdrawn from the study if they did not meet the cutoff. Following the CO assessment, participants rated their cravings to smoke using the Questionnaire on Smoking Urges (Cox et al., 2001) and then received 20 minutes of their assigned tDCS dosage during a laboratory smoking lapse paradigm.

2.3 Smoking lapse paradigm

The smoking lapse paradigm was identical to that used in our prior study based on the design by McKee and colleagues (McKee et al., 2012) and adapted for tDCS co-administration (Falcone et al., 2016). This paradigm is designed to model lapse behavior during abstinence, where the decision to choose an immediate reward (smoking a cigarette) over a delayed reward (improved health outcomes) can lead to smoking relapse. The paradigm targets two critical features of lapse behavior: the ability to resist smoking during abstinence and choices regarding subsequent smoking following a lapse (McKee et al., 2012). Monetary rewards are used as an alternative reinforcer to model the tradeoffs between immediate and delayed rewards. Participants were escorted to a 10×10 room equipped with industrial grade exhaust fans approved for exhaust of cigarette smoke, a comfortable couch, coffee table, and magazines. pack of the participant’s preferred brand of cigarettes was placed in view on the table in addition to a lighter and an ashtray. For the entirety of the session participants were asked to not use their phone, fall asleep, or eat, but they were permitted to read and drink water. Prior to tDCS administration, participants were instructed that during the next 50 minutes (the “resist” period) they would have the opportunity to smoke or to earn money by not smoking. For every 5 minutes that they were able to resist smoking, they would receive \$1, up to a maximum of \$10. At any point they were able to give in and smoke, but they would only receive the money earned up until that point. The tDCS administration took place during the first 20 minutes (see “tDCS procedures” below for more details); however, the tDCS equipment remained in place for the entire 50-minute resist period. We viewed the instruction to “try to resist smoking” as a “task” which would engage the executive control network targeted by the stimulation.

Following the resist period, the tDCS equipment was removed, and participants began an *ad libitum* smoking period that lasted 60 minutes. At this time 8 cigarettes were placed in front of the participant, and they were instructed that they had a \$4 tab with the researchers. They could smoke as many or as few of the cigarettes as they would like, but for every cigarette smoked \$0.50 was removed from the tab, and at the end of the 60 minutes the participant received any remaining balance. Participant smoking behavior was monitored during the session, and each cigarette smoked was video recorded on a Panasonic HC-V279 camera for validation. The outcomes for this paradigm are time to first cigarette and total number of cigarettes smoked; these measures are sensitive to the effects of efficacious smoking cessation medications such as varenicline and bupropion (McKee et al., 2012).

2.4 tDCS procedures

A trained technician DC-Stimulator Plus system. The device was employed in study mode, which facilitates blinding of both the participant and technician. This mode allows the assignment of a collection of five-digit codes to each treatment group; the randomization procedure applied by the data management team supplies a code for the tDCS technician to input into the device. Current was administered via 5 cm x 5 cm electrodes covered with saline-soaked sponges. The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3 in the international 10–20 system for EEG), and the cathodal electrode was placed over the right supraorbital area (FP2 in the 10–20 system). In the two active tDCS conditions, current was ramped up to the target dose (1mA or 2mA) over 30s, held constant for 19 min, and then ramped down over 30s (total stimulation time 20 min). In the sham tDCS condition, current was initially ramped up to 2mA over 30 seconds and immediately ramped down to 0mA. This procedure was repeated at the end of the 20 min session. These brief ramped up and down periods were delivered to aid the blinding so that participants would experience scalp sensations typical of active tDCS (Gandiga et al., 2006), but this brief stimulation is unlikely to cause changes in cortical excitability (Keeser et al., 2011; Lang et al., 2004; Nitsche et al., 2003; Nitsche and Paulus, 2000; Stagg et al., 2013).

2.5 Seven-day monitored quit period

In accordance with a validated 7-day quit paradigm (Perkins et al., 2010; Perkins et al., 2008), participants received a 20-minute in-person counseling session following session 3 of tDCS to prepare them for their quit attempt. They were instructed to try to remain abstinent from 10PM that evening until after the last monitoring visit (for a total of 7 days). During this period, participants had 4 monitoring visits (days 6, 8, 10, and 12), during which they reported on their smoking behavior using a time line follow-back procedure, provided an exhaled CO reading to biochemically confirm reported abstinence, and rated their cravings to smoke (Cox et al., 2001). As in 7-day quit studies (Perkins and Lerman, 2014; Perkins et al., 2013b), participants received a \$15 cash bonus for each day of biochemically-verified abstinence. At the first monitoring visit (day 6), a CO reading of less than 10ppm (or at least a 50% reduction from the reading at their eligibility screen) was required to confirm abstinence (Sandberg et al., 2011), and at the remaining three visits (days 8, 10, 12) a CO reading of less than 5ppm was required to confirm abstinence (Perkins et al., 2013a; Perkins et al., 2013b). The primary outcome was total number of days of biochemically verified abstinence (Perkins and Lerman, 2014; Perkins et al., 2010; Perkins et al., 2008). As a

secondary outcome, we examined the change in mean number of cigarettes smoked per day during the quit period compared to baseline smoking rate, based on self-report (quit period minus baseline). In accordance with standard practice for smoking cessation trials, participants who did not attend the monitoring visits were assumed to be smoking but were excluded from the analysis of mean cigarettes per day as missing data.

2.6 Analysis

A planned interim analysis was conducted upon reaching a sample size of $n = 35$ per dose group. Descriptive statistics were obtained for all variables. ANOVA and χ^2 tests were used to examine baseline differences in demographics between dose groups. The primary analysis utilized multiple regression modeling (Stata; StataCorp LLC, College Station, TX, USA) to estimate the effects of dose group on total number of days of biochemically-verified abstinence during the monitored abstinence period; age, sex, race, and nicotine dependence (FTND score) were included as covariates. Secondary analyses used similar models to examine effects of dose group on change in mean CPD (quit period minus baseline) and dose by session interaction effects on latency to smoke and total number of cigarettes smoked during the smoking lapse paradigm. Age, sex, race, nicotine dependence, and pre-session craving for negative affect relief (QSU-B Factor 2) were included as covariates in the models of the smoking lapse paradigm outcomes based on prior associations with latency to smoke using this paradigm (Falcone et al., 2016; McKee et al., 2012; Roche et al., 2014). Although post-session craving was confounded by whether or not the participant chose to smoke during the laboratory session, as an exploratory analysis we examined effects of dose group on change in pre-session craving (session 3 minus session 1). This analysis utilized multiple regression and controlled for the same covariates listed above.

3. Results

3.1 Descriptive data

One hundred and six subjects completed all three tDCS sessions. The sample was predominantly male ($n = 68$, 64%) and African-American ($n = 77$, 73%); most had completed at least some college or beyond ($n = 68$, 64%). The mean age was 45.3 years (SD 9.9), the mean CPD was 16.3 (SD 5.8), the mean expired CO at the eligibility screen was 16.6 ppm (SD 6.5), and the mean FTND score was 5.2 (SD 1.6). There were no differences in demographics or baseline smoking behavior between dose groups ($p > 0.4$ for all; Table 1). The majority of participants (69%) reported at least one prior quit attempt in their lifetime, and the average duration of the longest prior quit period was 9.8 months (range: 2 days to 10 years); however, all participants had been daily smokers of at least 10 CPD for the past year.

Expired CO readings at the start of the tDCS sessions were significantly reduced compared to the eligibility screen [Session 1, M (SD): 4.3ppm (2.1); Session 2: 5.4ppm (3.3); Session 3: 5.1ppm (3.3); $p < 0.0001$ for all], which indicates compliance with the abstinence requirement. Participants reported abstaining from cigarettes for a mean of 18.1 hrs. (range: 7–25 hrs.) prior to all sessions; this did not differ by session or dose group (p -values > 0.1).

3.2 Primary outcome

Results of the multiple regression model showed no association between dose group and total number of days of CO-verified abstinence during the quit period (sham, M (SD): 2.5 days (± 2.5); 1mA: 2.5 days (± 2.5); 2mA: 2.4 days (± 2.3); $\beta = -0.08$; $p = 0.76$, Figure 2A).

3.3 Secondary outcomes

In the multiple regression model, there was no association between dose group and change in mean from baseline to quit period [sham, M (SD): -12.6 CPD (± 4.8); 1mA: -11.8 CPD (± 4.4); 2mA: -11.7 CPD (± 5.3); $\beta = 0.42$, $p = 0.49$; Figure 2B]. There were no main effects of dose group or session and no significant dose group by session interaction effects on either latency to smoke or total number of cigarettes smoked during the sessions ($p > 0.1$ for all; Figure 2C-D). Age was positively associated with latency to smoke ($\beta = 0.74$, $p = 0.008$) and negatively associated with total number of cigarettes smoked across all sessions ($\beta = -0.02$, $p = 0.02$). There were significant associations between sex and lapse paradigm outcomes: women showed greater latency to smoke ($\beta = 14.3$, $p = 0.013$) and smoked fewer total cigarettes during the sessions ($\beta = -0.56$, $p = 0.003$). Urge to smoke for negative reinforcement (QSU-B Factor 2) was negatively associated with latency to smoke ($\beta = -0.97$, $p < 0.001$) and positively associated with total number of cigarettes smoked ($\beta = 0.02$, $p = 0.015$) across all sessions. Neither race nor nicotine dependence were associated with either of the secondary outcomes (p -values > 0.05). In the exploratory analysis, there was no effect of dose group on change in pre-session craving ($p = 0.3$; Figure 2E).

3.4 tDCS side effects and blinding

Side effects of tDCS were generally mild (< 5 out of 10) and (with one exception) did not differ between dose groups (p -values > 0.05 ; Table 2). The exception was for reports of itching at Session 3; participants in the 1mA group experienced greater itching at the site of the electrodes during stimulation compared to other groups ($p = 0.02$). At the end of each session, participants were asked to guess whether they received active or sham stimulation. Approximately 85% of participants believed they received real stimulation at each session, and this did not differ by session or dose group (p -values > 0.5).

3.5 Conditional power analysis

We conducted a futility analysis based on conditional power (futility = conditional power $< 20\%$) using results from the mixed model with dose of 1mA and 2mA lumped. Conditional power was calculated using PASS v15 (Power and Sample Size, NCSS Software, Kaysville, UT). Conditional power is the probability of rejecting the null hypothesis given the data already revealed; data that have not been revealed yet are assumed to follow the original assumed effect size. We used the z-score for the comparison of sham with lumped active treatment ($z = 0.04$, $p = 0.96$, effect size = 0.01) combined with the original design effect size of $d = 0.45$. Conditional power was 0.13, indicating that the study should be abandoned for futility (Proschan et al., 2006).

4. Discussion

In the largest study of the effects of tDCS on smoking behavior reported to date, we found no evidence for effects of three sessions of tDCS on the ability to remain abstinent during a 7-day short-term quit period. Furthermore, we also found no evidence for acute effects of tDCS on change in number of cigarettes per day from baseline or on the ability to resist smoking during a validated smoking lapse paradigm. The conditional power analysis performed after the interim analysis suggested that the study be terminated early. These findings do not support further development of this particular tDCS paradigm as an adjunctive treatment for smoking cessation.

The absence of a tDCS effect on latency to smoke and number of cigarettes smoked during the laboratory sessions contradicts a previous report using this laboratory paradigm (Falcone et al., 2016). However, the prior trial utilized a within-subject design with one session each of active and sham stimulation (separated by a two-week washout period to minimize carryover effects). Although the study was double-blind, and participants in that study were not able to identify the sessions in which they received active and sham stimulation at rates higher than chance, they were debriefed at the end of the study and asked to make a retrospective judgement. It may be that the sensations produced by sham stimulation are different than those produced by active stimulation and that this biases immediate expectations regarding treatment and smoking behavior (Falcone et al., 2016). The current study utilized a between-subject design, and participant beliefs were assessed at the end of each session. Participants were not able to correctly guess which type of stimulation they had received; approximately 85% of participants in all treatment groups believed they had received active stimulation, suggesting effective blinding in the current study.

A few other studies utilizing a between-subject design in smokers observed significant benefits of tDCS on craving and smoking behavior (Boggio et al., 2009; Vitor de Souza Brangioni et al., 2018). Boggio and colleagues (2009) reported a significant and cumulative reduction in craving in participants receiving active tDCS (compared to sham) over the course of five treatment sessions and a significant reduction in the number of cigarettes smoked during the treatment period in the active condition (although participants were not actively attempting to quit or reduce their smoking). Others have similarly observed reductions in smoking quantity despite no specific instructions to reduce smoking (Fecteau et al., 2014). Vitor de Souza Brangioni and colleagues (2018) observed a significant reduction in daily smoking quantity four weeks after treatment in the active treatment group compared to sham in smokers who were attempting to quit. Although measurement of daily smoking quantity during the treatment period in our current study would be confounded by our requirement for participants to remain abstinent for 18 hours prior to each session, we did not observe effects of tDCS on smoking quantity during the 7-day quit period. One possible reason for the difference in outcomes is that participants in the prior studies received a total of five tDCS sessions (compared to three sessions in our current study). It is possible that more sessions are necessary in order to observe a persistent effect. However, other studies have observed no effect of five sessions of active 2mA tDCS (versus sham) on craving or cigarette consumption in smokers with schizophrenia who were not instructed to alter their smoking behavior (Smith et al., 2015) and no effect of 10 sessions of 2mA tDCS

on cigarette consumption in healthy smokers who were highly motivated to quit (but not specifically instructed to do so) (Mondino et al., 2018). Within-subject designs also show mixed results: although several studies report decreased craving following active tDCS compared to sham (Fecteau et al., 2014; Fregni et al., 2008; Yang et al., 2017), others show no changes (Pripfl and Lamm, 2015; Xu et al., 2013). Studies of tDCS effects on smoking behavior have varied in baseline smoking rates among participants; it is possible that the variability in outcomes may relate to differences in tDCS effects among lighter versus heavier smokers. Although the number of heavier smokers (> 20 CPD) in our sample was too small to test for an interaction effect, it may be useful for future studies to examine whether baseline smoking quantity influences tDCS effects or whether tDCS influences puffing topography (e.g., puff latency, puff volume, or length of remaining cigarette).

Furthermore, although our intended target was anodal stimulation of the left DLPFC, tDCS can result in widespread changes in brain activation outside of the targeted region (Stagg et al., 2013). The tDCS montage consists of both an anode and a cathode, and the flow of current is influenced by both. Our hypothesis was that anodal stimulation of the left DLPFC would increase the ability to resist smoking by enhancing executive control; we chose the montage used in this study (anodal electrode over F3, cathodal over contralateral supraorbital area) based on studies showing beneficial effects for executive function (Andrews et al., 2011; Teo et al., 2011; Vanderhasselt et al., 2013) and smoking behavior (Falcone et al., 2016; Vitor de Souza Brangioni et al., 2018). However, fMRI studies using this montage have shown widespread changes in activation and functional connectivity beyond the DLPFC (Keeser et al., 2011; Stagg et al., 2013). In addition, some studies which have demonstrated beneficial effects of anodal stimulation of the left DLPFC for smoking behavior have varied in the placement of the cathodal electrode; for example, some have used a larger cathodal electrode to reduce the current density in underlying regions (Boggio et al., 2009; Mondino et al., 2018), others placed the cathode over the right DLPFC for bilateral stimulation (Fregni et al., 2008), and others used a reversed bilateral (anodal right, cathodal left) montage (Fecteau et al., 2014). Further research is necessary in order to understand the effects of tDCS montage on stimulation of the targeted region and nearby regions (Bikson et al., 2018; Tremblay et al., 2014). Collectively, these results highlight the need for a better understanding of factors contributing to tDCS outcomes in order to optimize treatment approach.

Although our findings do not support further development of tDCS as a treatment for smoking cessation, other brain stimulation modalities have shown promise for nicotine addiction and other substance use disorders (Coles et al., 2018; Hanlon et al., 2018). Repetitive transcranial magnetic stimulation (TMS) is a modality in which magnetic fields are used to induce temporary electrical currents in targeted cortical regions (Hallett, 2007). The majority of studies examining TMS in smokers found that stimulation of the DLPFC reduced cravings and/or cigarette consumption (Coles et al., 2018), with one exception (Li et al., 2017). Across substances, reduction in craving following stimulation of the DLPFC is a common finding; however, translating those reductions to changes in behavior is less consistent (Coles et al., 2018; Hanlon et al., 2018; Wing et al., 2013).

4.1 Strengths and limitations

Strengths of this study include the large sample size, the inclusion of treatment-seeking smokers (who may respond differently to treatment compared to non-treatment seekers) (Perkins et al., 2008), and biochemical confirmation of abstinence during the 7-day quit attempt. Abstinence during the first week of a quit attempt has been shown to significantly predict cessation at 6 months post-target quit date (Ashare et al., 2013). Abstinence rates observed during the quit attempt are similar to those observed in validation studies of the 7-day quit paradigm (Perkins and Lerman, 2014); the failure of tDCS to increase days of abstinence in this trial therefore does not support a clinical benefit.

Potential limitations of the study include the timing of tDCS administration and the concurrent task chosen to engage the relevant neural circuits during stimulation. Participants in our study received tDCS at the start of the smoking lapse paradigm when they were 18 hours abstinent. Prior studies have shown that nicotine withdrawal may impair tDCS-induced neuroplasticity (Grundey et al., 2012), which may have limited the potential persistent effects in our study. We chose to administer tDCS while participants were abstinent because we viewed the task of “resisting the urge to smoke while abstinent” as a training task that would engage the neural circuits targeted by tDCS, and abstinence was therefore a necessary condition. However, future research utilizing a different training task, such as a response inhibition task (Houben et al., 2011) which can be administered while smokers are not in withdrawal, may have a greater chance of observing persistent effects. It is also possible that a 3-day treatment protocol may not be sufficient to induce the required neuroplasticity to elicit tangible and durable effects on cravings and cigarette consumption. Longer protocols, similar to those used to study the antidepressant effects of tDCS, may be required (Loo et al., 2018). Our study sample consisted of a high proportion (~73%) of African-American smokers, which reflects the demographics of our location in west Philadelphia, Pennsylvania. Although this proportion is higher than observed in the general population of smokers in the United States (Jamal et al., 2018), race was not significantly associated with any of the outcomes, and the study was underpowered to test whether race moderates the impact of tDCS.

5. Conclusions

Recent research into non-invasive brain stimulation techniques such as tDCS has shown highly variable results for effects on smoking behavior. Our findings suggest that three sessions of anodal tDCS targeted to the left DLPFC are not sufficient to induce persistent effects on smoking behavior in treatment-seeking smokers. Further research aimed at understanding and optimizing factors contributing to tDCS outcomes would be beneficial for the field, as would studies of alternative forms of neuromodulation

Acknowledgments

Role of the Funding Source

This work was supported by the National Institutes of Health [R35CA197461 to C.L.]. The funding source had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the article for publication.

References

- Andrews SC, Hoy KE, Enticott PG, Daskalakis ZJ, Fitzgerald PB, 2011 Improving working memory: The effect of combining cognitive activity and anodal transcranial direct current stimulation to the left dorsolateral prefrontal cortex. *Brain Stimul* 4, 84–89. [PubMed: 21511208]
- Ashare RL, Falcone M, Lerman C, 2014 Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment. *Neuropharmacology* 76 Pt. B, 581–591. [PubMed: 23639437]
- Ashare RL, Wileyto EP, Perkins KA, Schnoll RA, 2013 The first 7 days of a quit attempt predicts relapse: Validation of a measure for screening medications for nicotine dependence. *J. Addict. Med* 7, 249–254. [PubMed: 23669629]
- Aubin HJ, Luquiens A, Berlin I, 2014 Pharmacotherapy for smoking cessation: Pharmacological principles and clinical practice. *Br. J. Clin. Pharmacol* 77, 324–336. [PubMed: 23488726]
- Babb S, Malarcher A, Schauer G, Asman K, Jamal A, 2017 Quitting smoking among adults— United States, 2000–2015. *WR Morb. Mortal. Wkly. Rep* 65, 1457–1464.
- Bikson M, Brunoni AR, Charvet LE, Clark VP, Cohen LG, Deng ZD, Dmochowski J, Edwards DJ, Frohlich F, Kappenman ES, Lim KO, Loo C, Mantovani A, McMullen DP, Parra LC, Pearson M, Richardson JD, Rumsey JM, Sehatpour P, Sommers D, Unal G, Wassermann EM, Woods AJ, Lisanby SH, 2018 Rigor and reproducibility in research with transcranial electrical stimulation: An NIMH-sponsored workshop. *Brain Stimul* 11, 465–480. [PubMed: 29398575]
- Boggio S, Liguori P, Sultani N, Rezende L, Fecteau S, Fregni F, 2009 Cumulative priming effects of cortical stimulation on smoking cue-induced craving. *Neurosci. Lett* 463, 82–86. [PubMed: 19619607]
- Botvinick M, Braver T, 2014 Motivation and cognitive control: From behavior to neural mechanism. *Annu. Rev. Psychol* 66, 83–113. [PubMed: 25251491]
- Braver TS, Krug MK, Chiew KS, Kool W, Westbrook JA, Clement NJ, Adcock RA, Barch DM, Botvinick MM, Carver CS, Cools R, Custers R, Dickinson A, Dweck CS, Fishbach A, Gollwitzer PM, Hess TM, Isaacowitz DM, Mather M, Murayama K, Pessoa L, Samanez-Larkin GR, Somerville LH, MOMCAI Group, 2014 Mechanisms of motivation-cognition interaction: Challenges and opportunities. *Cogn. Affect. Behav. Neurosci* 14, 443–472. [PubMed: 24920442]
- Cole DM, Beckmann CF, Long CJ, Matthews M, Durcan MJ, Beaver JD, 2010 Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics. *euroimage* 52, 590–599.
- Coles AS, Kozak K, George TP, 2018 review of brain stimulation methods to treat substance use disorders. *Am. J. Addict* 27, 71–91. [PubMed: 29457674]
- Cox LS, Tiffany ST, Christen AG, 2001 Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. *Nicotine Tob. Res* 3, 7–16. [PubMed: 11260806]
- D’Esposito M, Postle BR, 2014 The cognitive neuroscience of working memory. *Annu. Rev. Psychol* 66, 115–142. [PubMed: 25251486]
- Falcone M, Bernardo L, Ashare RL, Hamilton R, Faseyitan O, McKee SA, Loughhead J, Lerman C, 2016 Transcranial direct current brain stimulation increases ability to resist smoking. *Brain Stimul* 9, 191–196. [PubMed: 26572280]
- Fassbender C, Murphy K, Foxe JJ, Wylie GR, Javitt DC, Robertson IH, Garavan H, 2004 A topography of executive functions and their interactions revealed by functional magnetic resonance imaging. *Brain Res. Cogn. Brain Res* 20, 132–143. [PubMed: 15183386]
- Fecteau S, Agosta S, Hone-Blanchet A, Fregni F, Boggio P, Ciraulo D, Pascual-Leone A, 2014 Modulation of smoking and decision-making behaviors with transcranial direct current stimulation in tobacco smokers: A preliminary study. *Drug Alcohol Depend* 140, 78–84. [PubMed: 24814566]
- Fedota JR, Ding X, Matous AL, Salmeron BJ, McKenna MR, Gu H, Ross TJ, Stein EA, 2018 Nicotine abstinence influences the calculation of salience in discrete insular circuits. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* 3, 150–159. [PubMed: 29529410]
- Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME, 2005 The human brain is intrinsically organized into dynamic, anticorrelated functional networks. *Proc. Natl. Acad. Sci. U.S.A* 102, 9673–9678. [PubMed: 15976020]

- Fregni F, Liguori P, Fecteau S, Nitsche MA, Pascual-Leone A, Boggio PS, 2008 Cortical stimulation of the prefrontal cortex with transcranial direct current stimulation reduces cue-provoked smoking craving: A randomized, sham-controlled study. *J. Clin. Psychiatry* 69, 32–40.
- Gandiga PC, Hummel FC, Cohen LG, 2006 Transcranial DC stimulation (tDCS): A tool for double-blind sham-controlled clinical studies in brain stimulation. *Clin. Neurophysiol* 117, 845–850. [PubMed: 16427357]
- Global Burden of Disease Research Foundation Collaborators, 2016 Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 388, 1659–1724. [PubMed: 27733284]
- Grundey J, Thirugnanasambandam N, Kaminsky K, Drees A, Skwirba AC, Lang N, Paulus W, Nitsche MA, 2012 Neuroplasticity in cigarette smokers is altered under withdrawal and partially restituted by nicotine exposition. *J. Neurosci* 32, 4156–4162. [PubMed: 22442079]
- Hallett M, 2007 Transcranial magnetic stimulation: A primer. *Neuron* 55, 187–199. [PubMed: 17640522]
- Hanlon CA, Dowdle LT, Henderson JS, 2018 Modulating neural circuits with transcranial magnetic stimulation: Implications for addiction treatment development. *Pharmacol. Rev* 70, 661–683. [PubMed: 29945899]
- Houben K, Nederkoorn C, Wiers RW, Jansen A, 2011 Resisting temptation: Decreasing alcohol-related affect and drinking behavior by training response inhibition. *Drug Alcohol Depend* 116, 132–136. [PubMed: 21288663]
- Hughes JR, Keely J, Naud S, 2004 Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 99, 29–38. [PubMed: 14678060]
- Hyland A, Borland R, Li Q, Yong HH, McNeill A, Fong GT, O'Connor RJ, Cummings KM, 2006 Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey. *Tob. Control* 15 Suppl. 3, iii83–iii94. [PubMed: 16754952]
- Jamal A, Phillips E, Gentzke AS, Homa DM, Babb SD, King BA, Neff LJ, 2018 Current cigarette smoking among adults—United States, 2016. *MMWR Morb. Mortal. Wkly. Rep* 67, 53–59. [PubMed: 29346338]
- Keeser D, Meindl T, Bor J, Palm U, Pogarell O, Mulert C, Brunelin J, Moller HJ, Reiser M, Padberg F, 2011 Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. *J. Neurosci* 31, 15284–15293. [PubMed: 22031874]
- Kroczyk AM, Haussinger FB, Rohe T, Schneider S, Plewnia C, Batra A, Fallgatter AJ, Ehlis AC, 2016 Effects of transcranial direct current stimulation on craving, heart-rate variability and prefrontal hemodynamics during smoking cue exposure. *Drug Alcohol Depend* 168, 123–127. [PubMed: 27639130]
- Lerman C, Gu H, Loughhead J, Ruparel K, Yang Y, Stein EA, 2014 Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function. *JAMA Psychiatry* 71, 523–530. [PubMed: 24622915]
- Li X, Du L, Sahlem GL, Badran BW, Henderson S, George MS, 2017 Repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex reduces resting-state insula activity and modulates functional connectivity of the orbitofrontal cortex in cigarette smokers. *Drug Alcohol Depend* 174, 98–105. [PubMed: 28319755]
- Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM, McClintock SM, Mohan A, Lisanby SH, International Consortium of Research in t.D.C.S., 2018 International randomized-controlled trial of transcranial Direct Current Stimulation in depression. *Brain Stimul* 11, 125–133.
- Loughhead J, Wileyto EP, Ruparel K, Falcone M, Hopson R, Gur R, Lerman C, 2015 Working memory-related neural activity predicts future smoking relapse. *Neuropsychopharmacology* 40, 1311–1320. [PubMed: 25469682]
- McClellon FJ, Addicott MA, Sweitzer MM, 2015 Smoking abstinence and neurocognition: Implications for cessation and relapse. *Curr. Top. Behav. Neurosci* 23, 193–227. [PubMed: 25655892]

- McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S, 2012 Developing and validating a human laboratory model to screen medications for smoking cessation. *Nicotine Tob. Res* 14, 1362–1371. [PubMed: 22492085]
- Mondino M, Luck D, Grot S, Januel D, Suaud-Chagny MF, Poulet E, Brunelin J, 2018 Effects of repeated transcranial direct current stimulation on smoking, craving and brain reactivity to smoking cues. *Sci. Rep* 8, 8724. [PubMed: 29880873]
- Nitsche MA, Fricke K, Henschke U, Schlitterlau A, Liebetanz D, Lang N, Henning S, Tergau F, Paulus W, 2003 Pharmacological modulation of cortical excitability shifts induced by transcranial direct current stimulation in humans. *J. Physiol* 553, 293–301. [PubMed: 12949224]
- Perkins KA, Karelitz JL, Jao NC, 2013a Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. *Nicotine Tob. Res* 15, 978–982. [PubMed: 22990219]
- Perkins KA, Lerman C, 2014 An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation. *Psychopharmacology* 231, 1–11. [PubMed: 24297304]
- Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KN, Jain A, 2010 Cross-validation of a new procedure for early screening of smoking cessation medications in humans. *Clin. Pharmacol. Ther* 88, 109–114. [PubMed: 20485335]
- Perkins KA, Lerman C, Karelitz JL, Jao NC, Chengappa KN, Sparks GM, 2013b Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. *Addiction* 108, 1962–1968. [PubMed: 23773319]
- Perkins KA, Lerman C, Stitzer M, Fonte CA, Briski JL, Scott JA, Chengappa KN, 2008 Development of procedures for early screening of smoking cessation medications in humans. *lin. Pharmacol. Ther* 84, 216–221.
- Piper M., Schlam TR, Cook JW, Sheffer MA, Smith SS, Loh WY, Bolt DM, Kim SY, Kaye JT, Hefner KR, Baker TB, 2011 Tobacco withdrawal components and their relations with cessation success. *Psychopharmacology* 216, 569–578. [PubMed: 21416234]
- Pripfl J, Lamm C, 2015 Focused transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex modulates specific domains of self-regulation. *Neurosci. Res* 91, 41–47. [PubMed: 25269861]
- Proschan M, Lan KKG, Wittes JT, 2006 Statistical monitoring of clinical trials Springer, New York.
- Roche DJ, Bujarski S, Moallem NR, Guzman I, Shapiro JR, Ray LA, 2014 Predictors of smoking lapse in a human laboratory paradigm. *Psychopharmacology* 231, 2889–2897. [PubMed: 24500677]
- Sandberg A, Skold CM, Grunewald J, Eklund A, Wheelock AM, 2011 Assessing recent smoking status by measuring exhaled carbon monoxide levels. *PLoS One* 6, e28864. [PubMed: 22194931]
- Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG, 2006 Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. *Psychopharmacology* 184, 637–644. [PubMed: 16261317]
- Smith RC, Boules S, Mattiuz S, Youssef M, Tobe RH, Sershen H, Lajtha A, Nolan K, Amiaz R, Davis JM, 2015 Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: A randomized controlled study. *Schizophr. Res* 168, 260–266. [PubMed: 26190299]
- SRNT Subcommittee on Biochemical Verification, 2002 Biochemical verification of tobacco use and cessation. *Nicotine Tob. Res* 4, 149–159. [PubMed: 12028847]
- Stagg CJ, Lin RL, Mezue M, Segerdahl A, Kong Y, Xie J, Tracey I, 2013 Widespread modulation of cerebral perfusion induced during and after transcranial direct current stimulation applied to the left dorsolateral prefrontal cortex. *J. Neurosci* 33, 11425–11431. [PubMed: 23843514]
- Teo F, Hoy KE, Daskalakis ZJ, Fitzgerald PB, 2011 Investigating the role of current strength in tDCS modulation of working memory performance in healthy controls. *Front. Psychiatry* 2, 45. [PubMed: 21811474]
- Tremblay S, Lepage JF, Latulipe-Loiselle A, Fregni F, Pascual-Leone A, Theoret H, 2014 The uncertain outcome of prefrontal tDCS. *Brain Stimul* 7, 773–783. [PubMed: 25456566]
- Vanderhasselt MA, De Raedt R, Brunoni AR, Campanha C, Baeken C, Remue J, Boggio PS, 2013 tDCS over the left prefrontal cortex enhances cognitive control for positive affective stimuli. *PLoS One* 8, e62219. [PubMed: 23704874]

- Vangeli E, Stapleton J, Smit ES, Borland R, West R, 2011 Predictors of attempts to stop smoking and their success in adult general population samples: A systematic review. *Addiction* 106, 2110–2121. [PubMed: 21752135]
- Vincent JL, Kahn I, Snyder AZ, Raichle E, Buckner RL, 2008 Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. *J. Neurophysiol* 100, 3328–3342. [PubMed: 18799601]
- Vitor de Souza Brangioni MC., Pereira DA, Thibaut A, Fregni F, Brasil-Neto JP, Boechat-Barros R, 2018 Effects of prefrontal transcranial direct current stimulation and motivation to quit in tobacco smokers: A randomized, sham controlled, double-blind trial. *Front. Pharmacol* 9, 14. [PubMed: 29434547]
- Wilcox CE, Calhoun VD, Rachakonda S, Claus ED, Littlewood RA, Mickey J, Arenella PB, Hutchison KE, 2017 Functional network connectivity predicts treatment outcome during treatment of nicotine use disorder. *Psychiatry Res. Neuroimaging* 265, 45–53. [PubMed: 28525877]
- Wing VC, Barr MS, Wass CE, Lipsman N, Lozano AM, Daskalakis ZJ, George TP, 2013 Brain stimulation methods to treat tobacco addiction. *Brain Stimul* 6, 221–230. [PubMed: 22809824]
- World Health Organization (WHO), 2017 WHO report on the global tobacco epidemic 2017 World Health Organization, Geneva.
- Xu J, Fregni F, Brody AL, Rahman AS, 2013 Transcranial direct current stimulation reduces negative affect but not cigarette craving in overnight abstinent smokers. *Front. Psychiatry* 4, 112. [PubMed: 24065930]
- Yang LZ, Shi B, Li H, Zhang W, Liu Y, Wang H, Zhou Y, Wang Y, Lv W, Ji X, Hudak J, Zhou Y, Fallgatter AJ, Zhang X, 2017 Electrical stimulation reduces smokers' craving by modulating the coupling between dorsal lateral prefrontal cortex and parahippocampal gyrus. *Soc. Cogn. Affect. Neurosci* 12, 1296–1302. [PubMed: 28398588]

Highlights

- We examined effects of anodal transcranial direct current stimulation (tDCS) targeted to the left dorsolateral prefrontal cortex (DLPFC) on smoking behavior.
- 1mA or 2mA tDCS (vs. sham) had no effect on days of abstinence or smoking rates.
- Active tDCS (vs. sham) did not improve ability to resist smoking in the laboratory.

Figure 1:

CONSORT Participant Flow Diagram. Compared to participants who completed the study, participants who withdrew after randomization but before receiving stimulation ($n = 23$) were younger [mean (SD) 39.2 (12.3) years for those who withdrew vs. 45.3 years for study completers] and more likely to be white (52% of those who withdrew vs. 24% of study completers). Compared to study completers, participants who withdrew after receiving at least one stimulation session ($n = 12$) were more likely to be white (58% of those who withdrew vs. 24% of study completers) and were heavier smokers at baseline (mean 21.4 PD vs. 15.3 CPD among study completers). There were no other differences in baseline demographics or smoking history between study completers and participants who withdrew.

Figure 2:

Smoking Outcomes by Dose Group. There were no significant effects of tDCS on A) the total number of days of abstinence during the quit period, or B) change in average number of cigarettes smoked per day during the quit period compared to baseline; $p_s > 0.4$). There were no significant session by dose group interaction effects on C) overall latency to smoke during the laboratory period, or D) total cigarettes smoked during the laboratory sessions ($p_s > 0.1$). E) There was no significant effect of dose group on change in pre-session craving to smoke ($p = 0.3$).

Table 1.

Demographics by Dose Group

Measure	Sham group (n = 35)	1mA group (n = 35)	2mA group (n = 36)	p-value
Age, m (SD)	44.7 (11.2)	45.6 (9.4)	45.4 (9.2)	0.93
Sex, n (%) female	15 (43%)	13 (37%)	10 (28%)	0.41
Race, n (%)				
African American	24 (69%)	25 (71%)	28 (80%)	0.66
American Indian/Alaskan Native	0 (0%)	1 (3%)	0 (0%)	
Asian	0 (0%)	0 (0%)	1 (3%)	
White	10 (29%)	8 (23%)	7 (19%)	
More than one race	1 (3%)	1 (3%)	0 (0%)	
Education				
High school or less	13 (37%)	10 (29%)	15 (42%)	0.51
Some college/college grad	22 (63%)	25 (71%)	21 (58%)	
CPD, m (SD)	15.4 (4.8)	16.9 (6.3)	16.5 (6.1)	0.53
CO at eligibility (ppm), m (SD)	17.8 (6.9)	16.1 (6.6)	16.1 (6.1)	0.45
FTND score, m (SD)	5.3 (1.5)	5.1 (1.6)	5.1 (1.8)	0.84

Table 2.

Side Effects of tDCS at Session 3

Effect	Sham group (n = 35)	1mA group (n = 35)	2mA group (n = 36)	p-value
Tingling	2.7 (2.3)	3.9 (3.2)	3.4 (3.0)	0.23
Itching	2.7 (2.6)	4.6 (3.4)	3.1 (2.9)	0.02
Burning	1.9 (2.5)	2.0 (2.8)	2.8 (3.2)	0.31
Pain	0.8 (1.7)	0.9 (2.0)	1.2 (2.2)	0.72
Fatigue	1.5 (2.6)	2.1 (3.0)	1.7 (3.0)	0.70
Nervousness	1.3 (2.5)	0.4 (1.1)	0.5 (1.3)	0.08
Headache	0.6 (1.3)	0.6 (1.5)	0.3 (0.9)	0.52
Difficulty Concentrating	0.9 (1.9)	1.2 (2.0)	0.9 (2.2)	0.80
Mood Change	0.7 (1.8)	0.5 (1.0)	0.7 (1.7)	0.82
Change in Vision	0.8 (1.9)	0.5 (1.2)	0.5 (1.4)	0.68
Visual Sensation (lights)	5	6	8	0.68

Values shown are mean (SD) except for Visual Sensation (lights), which is n.